Love, Premiums, and the Weight-Loss Drug Arms Race Hits the Courtroom

Dating data, rising health care costs, and a GLP-1 courtroom fight | PoundsPunch Periodical | July 2026 Edition

Nobody expected a weight-loss drug to show up in places no ordinary prescription label could capture: dating data, insurance rate filings, and a federal courtroom. Yet that was July.

That sounds like four different stories. It is really one sign that the GLP-1 era has outgrown the doctor’s office.

This month, these medications appeared in research about romance and hiring, in the arithmetic behind our health care bills, and in a lawsuit between the two companies that turned obesity medicine into one of the biggest contests in pharma. In other words, GLP-1s are no longer just changing the number on the scale. They are changing the world around it.

Is “Ozempic Divorce” Real? Not So Fast.

The internet version of the story practically writes itself. Someone loses 50, 80, or 100 pounds. Confidence returns. Other people suddenly pay attention. New romantic possibilities appear. The person looks at an existing relationship and decides it no longer fits.

It is dramatic. But it is also mostly a story.

Some of the ideas may come from earlier research involving bariatric surgery. A large Swedish study found that people who underwent weight-loss surgery experienced both more new relationships and more divorces or separations than comparison groups. But surgery is not a GLP-1 prescription, and even that study could not prove that weight loss itself caused the relationship changes.

The newer GLP-1 research tells a rather different story.

Economist Rebecca Diamond compared women who started GLP-1 treatment for weight loss with similar women who wanted treatment but had not yet started. Among women who were single before treatment, marriage or cohabitation became considerably more common. Once the follow-up reached six or more quarters, the estimated difference was almost 29 percentage points. Among women who were already in relationships, however, the study found no increase in relationship breakups. So, at least among the women studied, the “Ozempic divorce” headline did not survive contact with the data. Almost 29 percentage points sounds enormous—and it is.

But that does not mean GLP-1 medications are bottled romance. The study cannot tell us exactly why new relationships increased. Weight loss could improve health, mobility, energy, or confidence. It could make someone more willing to date.

It could also change the way prospective partners respond to that person.

That last possibility may be the most uncomfortable. And this is the most interesting part.

The same research found that women who had been outside the workforce became more likely to find employment after starting treatment. Women who already had jobs, however, did not suddenly begin receiving more hours or moving up the corporate ladder.

That pattern led Diamond to suggest that body weight may matter most during a first impression: a first date, a job interview, or any moment when someone has limited information and appearance is allowed to carry too much weight.  

Perhaps the medication is not changing a woman’s value nearly as much as it changes other people’s willingness to recognize it. That may be the more revealing part of the story: not what weight loss did to an existing relationship, but what weight had been doing to the opportunity to start one. This is one early observational working paper involving women, not a final verdict on every relationship. But it did not find a GLP-1 breakup wave. It found more new relationships.

The Triple Whammy Driving Up Our Health Care Costs

For many of us, GLP-1 affordability starts with a blunt question at the pharmacy counter: Can I fit this prescription into the monthly budget?

July’s answer was that the prescription may be only the first bill. The same family trying to pay for a GLP-1 may also be paying more to keep hospitals and physician offices staffed, navigating tighter drug-coverage rules, and absorbing an insurance shock after enhanced ACA subsidies expired. Each pressure has a different origin. Together, they form a perfect storm.

Whammy No. 1: Hospitals and Physician Offices Are Paying More to Stay Open

Let’s begin with something that should not be controversial. Nurses, physicians, medical assistants, technicians, therapists, schedulers, and other health care workers deserve competitive pay.

The problem is not that they earn too much. The problem is that the health care system waited until a staffing crisis to confront how expensive an understaffed hospital or physician office really is. The pandemic-era staffing shock did not disappear when the public-health emergency ended. Hospitals and practices have continued competing for workers, raising salaries and benefits, replacing people who left, and paying more for medical supplies, technology, and outside services. The American Hospital Association reported that workforce costs increased 5.6% in 2025 and represented roughly 60% of hospital expenses. Medical-practice leaders responding to an MGMA survey reported that operating expenses had increased by an average of approximately 11.1% in 2025, with salaries, benefits, competitive pay adjustments, and medical supplies among the leading causes. Physician offices may not have emergency rooms or buildings large enough to occupy a city block, but they face the same basic squeeze. A practice that pays more to retain a nurse, recruit a medical assistant, purchase vaccines, maintain its electronic records, and keep the lights on must find that money somewhere.

Naturally, hospitals and physician groups ask insurers for higher reimbursement. Insurers build those higher provider payments into future premiums. Employers and public programs absorb part of the increase. Eventually, the rest reaches us.

That pattern is already visible in insurers’ 2027 rate filings, which cite rising hospital costs, physician visits, provider contract increases, labor shortages, and higher utilization as major reasons for higher premiums. The median assumed increase in underlying medical and prescription costs was 10%, up from roughly 8% in several recent years.

None of this means a nurse’s raise is the villain. Paying health care workers fairly and keeping local medical care available are good intentions. But the health care system has no secret account from which those costs disappear. The bill moves downstream—to insurers, employers, Medicare, taxpayers, and eventually us.

Whammy No. 2: More GLP-1 Access, More Gatekeeping

Then there is the medication itself. Consider the experience of Kyra Wensley: after losing 50 pounds on Zepbound, she received a letter saying her continuing coverage had been denied because her BMI had been below 35 when she originally began treatment. Her BMI had been around 32. Her physician fought the decision. Wensley eventually had to switch from Zepbound to Wegovy to satisfy her health plan’s requirements, even though she preferred the medication that had already been working for her.

The plan’s stated reason was its BMI rule. But in the larger market, rules like BMI thresholds, prior authorization, preferred-drug lists, quantity limits, and treatment-duration requirements also function as gates. They make the doorway into an expensive drug category narrower. The rule may be written in clinical language. Its practical effect is cost control. That is why Kyra’s story matters. It is not simply a strange dispute over whether her BMI began at 32 or 35. It shows what happens when a highly effective treatment meets a health plan that is trying to control a category with list prices around $1,000 per month and rapidly expanding demand.

The irony is hard to miss: The treatment works. The BMI falls. The lower BMI then becomes part of the argument for limiting the treatment that produced it. And while insurers are narrowing access in some places, policymakers are trying to widen it elsewhere.

On July 1, CMS launched the Medicare GLP-1 Bridge. The temporary program gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight-loss medications for a $50 monthly copayment through the end of 2027. It operates outside the normal Part D coverage and payment system, meaning Medicare created a separate pathway rather than simply making obesity drugs a standard Part D benefit.

As PoundsPunch explained in June, Medicare did not build a permanent house for weight-loss drug coverage. It built a bridge, which is genuine progress. But it also exposes the dilemma.

One part of the system sees the health benefits and tries to make treatment available to more of us. Another part sees the monthly claims and tightens the gate. We experience both as whiplash. This is not an argument against expanding access. It is an argument that access without a sustainable price eventually turns into another form of restriction.

Whammy No. 3: The Insurance Bill Hits Home

Then comes the insurance bill itself.

A preliminary analysis of filings from 77 ACA Marketplace insurers across 16 states and the District of Columbia found a median proposed premium increase of 14% for 2027. Most requests were between 10% and 20%, while 20 insurers requested increases above 20%.

Although those numbers may not necessarily be what each household will pay at the end of the day, some of us do not need a rate-filing spreadsheet to understand what this kind of pressure can mean. I watched it happen in my own family. My parents’ monthly ACA premium went from roughly $34 to more than $2,000 for the same coverage. They could not afford to keep it and ended up without insurance.

That is not a 14% story. It is a cliff.

A jump that large does not necessarily mean the underlying insurance policy became more than 60 times as expensive overnight. It can happen when a tax credit had been paying most of the gross premium and then disappears. The coverage may look the same, but the financing underneath it has changed. The expiration of the enhanced ACA tax credits brought back the subsidy cliff for households earning more than 400% of the federal poverty level. KFF found that average monthly premium payments after tax credits rose 58% in 2026, from $113 to $178. People with known incomes above the subsidy cliff represented only 7% of 2025 Marketplace enrollment but nearly half of the subsequent decline in plan selections.

February effectuated Marketplace enrollment fell from 21.8 million people in 2025 to 19.2 million in 2026. Not everyone who left became uninsured; some may have found coverage through work, Medicare, Medicaid, or another source. But in KFF polling, 9% of people who had Marketplace insurance in 2025 said they became uninsured for 2026, and eight in 10 who changed their ACA coverage or became uninsured cited cost as a reason.

Now imagine adding even three months of GLP-1 treatment to that household budget. And remember: these medications are generally used for chronic conditions. They are not necessarily a three-month course that ends once the scale reaches a preferred number. The ACA market is only one snapshot, but it is the part of the insurance system where many of us can see the pressure most clearly. We receive a monthly invoice with the premium printed directly on it. With employer-sponsored insurance, the increase is harder to decipher because the employer generally pays a large share of the premium. The cost may emerge through a larger payroll deduction, a higher deductible, more coinsurance, a narrower network, or the removal of a benefit instead of one shocking invoice.

Medicare costs can also surface through benefit changes, plan design, selective market exits, or reduced extras rather than a simple premium increase.

Several major publicly traded insurers used remarkably similar language in their recent earnings reports. UnitedHealth said ) that “pricing, benefit design and market actions” had been central to its improved results and discussed benefit adjustments and selective changes in market participation. Elevance Health (or Anthem) reported that higher premium yields supported revenue while Medicare Advantage, Medicaid, and employer risk membership declined. Centene said Marketplace rate increases and improved pricing helped restore profitability while its Marketplace membership fell from approximately 5.9 million to 3.5 million.

Wall Street calls this pricing discipline, margin restoration, benefit design, and selective market participation. For the rest of us, it can mean paying more, receiving fewer benefits, or discovering that the plan we used last year is no longer available. Public companies answer to shareholders. But the way they protect their margins is not abstract. We pick up the bill.

And an ACA plan does not necessarily solve the GLP-1 affordability problem. In KFF’s review of 2024 federal Marketplace formularies, Wegovy appeared on only 1% of plans, while all plans that covered obesity GLP-1 drugs required prior authorization. That analysis is now two years old, so it should not be treated as a current plan directory, but it shows how limited obesity-drug coverage has historically been in the Marketplace.

Still, an ACA plan can get us into a physician’s office. It can cover laboratory services, hospitalization, prescription benefits, preventive care, and chronic-disease management even when it does not cover the particular obesity medication we want. It can give us a safer and more reliable entrance into weight management than a mystery vial purchased through an unverified website. When insurance becomes unaffordable, we do not lose only a plastic card. We lose a doorway into the health care system.

When GLP-1 Advertising Goes to Court

The weight-loss drug arms race was already being fought through clinical trials, manufacturing plants, coupons, pills, pens, and television commercials. In July, it added lawyers.

Picture the argument. Lilly points to a randomized head-to-head clinical trial and says: Zepbound produced more weight loss than Wegovy.

Novo Nordisk responds: Yes—but you compared your strongest doses with an older, lower dose of our drug. We now have a higher one.

Normally, that disagreement might remain inside medical-conference presentations, sales meetings, and strongly worded corporate emails.

On July 21, it moved into federal court. Novo Nordisk sued Eli Lilly, alleging that national advertisements for Zepbound and Mounjaro create a misleading impression by comparing Lilly’s highest approved doses with lower doses of Wegovy and Ozempic. For the Zepbound comparison, the head-to-head study used Wegovy doses of 1.7 and 2.4 milligrams. The FDA has since approved a higher 7.2-milligram Wegovy dose that was not tested in that trial.

Novo’s position is that consumers are not being shown the most current version of the competition.

Lilly sees it differently. Its argument is that the most reliable comparison is the direct randomized trial that actually placed the two medications against each other. Separate studies can involve different people, different rules, different timelines, and different definitions of success. Lilly says the study used in its advertising remains the only randomized head-to-head trial directly comparing tirzepatide and semaglutide for weight management. The company says it stands behind the advertisements and will defend itself against Novo’s allegations.

This is where the fight becomes more interesting than ordinary corporate mudslinging. Lilly has a reasonable point: A direct head-to-head comparison is generally more persuasive than placing numbers from two unrelated studies next to each other. Novo also has a reasonable point: Consumers should be clearly told when the direct comparison did not include the newest and highest available dose of the competing medication.

Our view is that a fair advertisement should make both facts obvious. Lilly won the available head-to-head comparison. That comparison did not test Novo’s newer highest dose. Neither fact belongs in microscopic print racing across the bottom of a television screen. The court has not decided whether Lilly’s advertisements cross the legal line. Novo’s claims remain allegations, and Lilly disputes them. But the consumer lesson does not need to wait for a judge. Drug advertisements are not sports scoreboards. When an advertisement says one medication “beat” another, the complete sentence is usually much longer: One dose of one medication produced a better average result than particular doses of another medication, in a particular group of people, over a particular period, using a particular definition of success. That sentence does not fit neatly into a commercial. which is precisely why the missing details matter.

There is also some unavoidable irony here. The two companies telling us to trust the science are now fighting over which portion of the science we should see. In the weight-loss drug arms race, even the footnote has become a weapon.

---

Final Punch

Only a few years ago, the impact of a weight-loss medication would have been measured mainly in pounds, blood sugar, and side effects. Now it reaches relationships, hiring, physician offices, hospital budgets, insurance premiums, public policy, Wall Street, and federal court.

That is what is remarkable about a life-changing medicine: it forces us to reconsider what health care actually means. Health care is no longer only about the days when we are sick. It is also about prevention, opportunity, confidence, work, finances, access—and whether we can afford the chance to become healthier in the first place.

The prescription still comes in a box. Its true impact no longer fits inside one.